Treatment Trials Summary
1 Pharmacological Interventions
| Intervention | Study Type | Sample | Findings | Recommendation | Evidence |
|---|---|---|---|---|---|
| Low-Dose Naltrexone (LDN) | Observational | n=218 (Polo, Pesonen, and Tuominen 2019); n=42 Long COVID (Gottschalk et al. 2023) | 73.9% positive response (ME/CFS); 78% improved (Long COVID); improved vigilance, alertness, physical/cognitive performance | Consider trial; 3.0–4.5mg/day | MODERATE (large observational; no RCT) |
| Rituximab (B-cell depletion) | Phase III RCT | n=152 (Fluge et al. 2019); 6-year follow-up (Rekeland et al. 2024) | NO BENEFIT; placebo 35% response > rituximab 26%; no long-term benefit | DO NOT USE | HIGH (definitive negative) |
| Graded Exercise Therapy (GET) | Multiple studies; patient surveys | Patient harm reports; PACE trial discredited | Causes deterioration in many patients; violates PEM physiology | HARMFUL; contraindicated | HIGH (consensus; patient evidence) |
2 Patient-Reported Interventions
These interventions lack formal RCT validation but have plausible mechanisms and multiple independent patient reports. They require medical supervision and formal clinical trials.
| Intervention | Reported Dose | Reported Benefits | Plausible Mechanism | Research Status |
|---|---|---|---|---|
| Nicotine (low-dose) | 2–4mg/day (gum, patch) | Rapid brain fog improvement (hours to days); multiple independent reports | Alpha-7 nAChR modulation; anti-inflammatory; mitochondrial calcium regulation (ch19 Cholinergic-Mitochondrial Signaling Link) | HYPOTHESIS-GENERATING; needs RCT; addiction risk |
| Methylene blue | 1–5mg/day (very low dose) | Smell restoration, brain fog reduction within 1 week | Enhances electron transport; reduces oxidative stress; indirect benefit despite Complex IV dysfunction (ch19 Methylene Blue Electron Transport Enhancement) | HYPOTHESIS-GENERATING; dose-finding needed |
| Ketogenic diet | Strict keto | Dramatic improvement in subset; “medication-free” in some cases | Ketone bodies provide alternative fuel (acetyl-CoA) without glucose; reduces oxidative stress (ch19 Emerging Patient-Reported Interventions) | ANECDOTAL; subset-specific; needs stratified trial |
| Pyruvate (prophylactic) | 1–2g pre-exertion | Proposed to prevent PEM crashes | Provides pyruvate directly for TCA cycle; skips glycolysis requirement; used by athletes (ch19 Pyruvate for ATP Regeneration Bypass) | SPECULATIVE; testable in RCT |
| NAD+ precursors | NR 300–1000mg/day; NMN 250–500mg/day | Proposed for post-exertional recovery | Boosts lactate dehydrogenase; accelerates lactate clearance; improves mitochondrial NAD+/NADH ratio (ch19 nad lactate) | SPECULATIVE; mechanistically sound; testable |
3 Comorbidity Management
| Condition | Diagnostic Test | Presentation Overlap | Clinical Implication |
|---|---|---|---|
| Sleep Apnea | Polysomnography (overnight sleep study) | Fatigue, cognitive dysfunction, unrefreshing sleep; patient reports describe years of misdiagnosis | CPAP treatment can resolve symptoms; should be standard workup |
| Lyme Disease (European species) | European Lyme serology panel | Chronic fatigue, PEM-like symptoms; 10-year misdiagnosis reported | Long-cycle antibiotics “significantly helpful”; requires regional-specific testing (ch19 lyme mecfs overlap) |
| Hypermobile EDS (hEDS) | Beighton score; clinical assessment | Joint hypermobility, easy bruising, fatigue, POTS overlap; “100-fold underdiagnosed” | Physical therapy adaptations; affects pacing strategies (ch19 §eds mcas mecfs) |
| Mast Cell Activation (MCAS) | Tryptase levels; clinical criteria | Allergic symptoms, flushing, GI issues, fatigue | H1/H2 blockers, mast cell stabilizers may help; potential mito-immune link (ch19 Mast Cell Mediators Damage Mitochondria) |
| ADHD + hEDS overlap | Clinical assessment | Shared genetic factors proposed; frequent co-occurrence | May represent distinct phenotype requiring different management (ch19 §eds mcas mecfs) |
References
Fluge, Øystein, Ingrid G. Rekeland, Kristin Lien, Hilde Thürmer, Petter C. Borchgrevink, Christoph Schäfer, Kari Sørland, et al. 2019. “B-Lymphocyte Depletion in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.” Annals of Internal Medicine 170 (9): 585–93. https://doi.org/10.7326/M18-1451.
Gottschalk, Carl Gunnar, Ryan Whelan, Daniel Peterson, and Avik Roy. 2023. “Detection of Elevated Level of Tetrahydrobiopterin in Serum Samples of ME/CFS Patients with Orthostatic Intolerance: A Pilot Study.” International Journal of Molecular Sciences 24 (10): 8713. https://doi.org/10.3390/ijms24108713.
Polo, Olli, Pia Pesonen, and Essi Tuominen. 2019. “Low-Dose Naltrexone in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).” Fatigue: Biomedicine, Health & Behavior 7 (4): 207–17. https://doi.org/10.1080/21641846.2019.1692770.
Rekeland, Ingrid G., Kari Sørland, Linn L. Neteland, Alexander Fosså, Kari Alme, Kristin Risa, Olav Dahl, Karl J. Tronstad, Olav Mella, and Øystein Fluge. 2024. “Six-Year Follow-up of Participants in Two Clinical Trials of Rituximab or Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” PLoS One 19 (7): e0307484. https://doi.org/10.1371/journal.pone.0307484.